A decade on from the alarming association of cabergoline associated valvulopathy (CAV) in Parkinson’s disease, only 2 confirmed cases have occurred in prolactinoma patients. Routine screening for CAV by echocardiogram has not proven to be of diagnostic utility, has several limitations and is not widely practised. We have previously highlighted the value of annual cardiovascular examination as screening tool for CAV in prolactinoma patients. We present a case to highlight the value of the cardiovascular examination, which is now the third confirmed case of CAV. A 52 year old female with a 25 year history of macroprolactinoma had received multimodal treatment including surgery, radiosurgery and medical therapy. Her medical therapy initially consisted of bromocriptine followed by cabergoline. The cabergoline dose was 6mg weekly, and in 2009 the cumulative dose of 3272mg when an echocardiogram showed no evidence of valvular disease. A routine cardiovascular examination in clinic detected a new murmur in 2016. Echocardiogram demonstrated new onset mild- moderate aortic regurgitation, with a thickened and restricted valve consistent with CAV. Cumulative dose of cabergoline at this time was 4192mg. Follow up echocardiogram at six monthly intervals showed progression to moderate-severe aortic regurgitation, which has now stabilized. Cabergoline therapy was weaned and stopped completely in April 2017. Annual cardiovascular examination is the best screening test for CAV and can change the course of patient management. Echocardiograms should be reserved for patients with a new onset cardiac murmur or a high cumulative dose of cabergoline.